A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114)
Hagen P, Hoering A, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D’Souza A, Landau H, Rosenthal A, Ailawadhi S, Z. R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114). 2024 DOI: 10.26226/m.65f9bf89e6f73964e1d4eb32.Peer-Reviewed Original Research